Drug Toxicities in Second-Line Treatment of Chronic Myeloid Leukemia

被引：0
|
作者：
Datoguia, Tarcila S. [1 ]
Silva, Hugo R. C. [1 ]
Junior, Amauri M. C. R. [1 ]
Oliveira, Jose Salvador [1 ]
Conchon, Monika [1 ]
机构：
[1] Hosp Santa Marcelina, Hematol, Sao Paulo, Brazil
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML).
    Yood, M. Ulcickas
    Oliveria, S. A.
    Hirji, I.
    Phillips, S.
    Cziraky, M. J.
    Davis, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure
    Buyukasik, Yahya
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 4 - 9
  • [23] Second-Line Therapy for Patients With Chronic Myeloid Leukemia Resistant to First-Line Imatinib
    Lau, Anna
    Seiter, Karen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (03): : 186 - 196
  • [24] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    Muresan, B.
    Mamolo, C.
    Cappelleri, J. C.
    Postma, M. J.
    Heeg, B.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (06) : 929 - 940
  • [25] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    B. Muresan
    C. Mamolo
    J. C. Cappelleri
    M. J. Postma
    B. Heeg
    Applied Health Economics and Health Policy, 2021, 19 : 929 - 940
  • [26] Bosutinib as Third-Line Treatment for Chronic Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy with Dasatinib or Nilotinib
    Khoury, H. Jean
    Kim, Dong-Wook
    Zaritskey, Andrey
    Gambacorti-Passerini, Carlo
    Hochhaus, Andreas
    Navarro, Juan
    Rapoport, Aaron P.
    Dorlhiac-Llacer, Pedro Enrique
    Zanichelli, Maria
    Kelly, Virginia
    Besson, Nadine
    McMullan, Trevor
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2010, 116 (21) : 391 - 391
  • [27] Nilotinib As Second-Line Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase: Thailand Experience
    Chansung, Kanchana
    Sirijerachai, Chittima
    Lekhakula, Arnuparp
    Viboonjuntra, Pongtep
    Niparuck, Pimjai
    Pauvilai, Teeraya
    Numbenjapon, Tontanai
    Bunworasate, Udomsak
    Nawarawong, Weerasak
    Tantiworawit, Adisak
    Suwanban, Tawatchai
    Jootar, Saengsuree
    BLOOD, 2016, 128 (22)
  • [28] Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia
    Ayyildiz, O
    Isikdogan, A
    Bolaman, Z
    Muftuoglu, E
    SAUDI MEDICAL JOURNAL, 2004, 25 (12) : 2054 - 2056
  • [29] Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia
    Norbert Niederle
    Dirk Megdenberg
    Leopold Balleisen
    Wolfgang Heit
    Wolfgang Knauf
    Johann Weiß
    Werner Freier
    Axel Hinke
    Stefan Ibach
    Hartmut Eimermacher
    Annals of Hematology, 2013, 92 : 653 - 660
  • [30] Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia
    Niederle, Norbert
    Megdenberg, Dirk
    Balleisen, Leopold
    Heit, Wolfgang
    Knauf, Wolfgang
    Weiss, Johann
    Freier, Werner
    Hinke, Axel
    Ibach, Stefan
    Eimermacher, Hartmut
    ANNALS OF HEMATOLOGY, 2013, 92 (05) : 653 - 660
12345